Moderate to Severe Rheumatoid ArthritisUP-RISINGNCT06712628
A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
An observational study of Moderate to Severe Rheumatoid Arthritis, run by AbbVie at 75 sites in Germany.
Trial summary
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Moderate to Severe Rheumatoid Arthritis
- How many people
- 678 participants
- Where
- 75 sitesGermany
- Study dates
- 7 Nov 2024to Dec 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Participants with moderate to severe active Rheumatoid Arthritis receiving Upadcitinib or a Tumor necrosis factor inhibitor treatment.
Who may be able to join
- Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician.
- Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study
- UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies
Who cannot join
- Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug [whichever is longer] prior to baseline)
- Prior treatment with Upadacitinib
- Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study
Trial locations and contacts
75 sites in 1 country. Contact the study team or a site near you to ask about taking part.
75 sites in 1 country
Germany75 sites, 74 recruiting
- Recruiting
Private Practice - Dr. Thomas Kupka /ID# 273631
Altenburg, Thuringia, 04600
- Recruiting
Dr. Med. Thomas Marycz /ID# 274646
Amberg, Bavaria, 92224
- Recruiting
Rheumapraxis Am Webereck /ID# 274412
Augsburg, Bavaria, 86157
- Recruiting
Rheumatism Center Mittelhessen /ID# 274641
Bad Endenbach, Hesse, 35080
- Completed
MVZ Weserbergland /ID# 276009
Bad Pyrmont, 31812
- Recruiting
Private Practice - Dr. Karin Manger /ID# 287347
Bamberg, Bavaria, 96047
- Recruiting
Rheumapraxis Steglitz /ID# 280323
Berlin, 10777
- Recruiting
Private Practice - Dr. Silke Zinke /ID# 276366
Berlin, 13055
- Recruiting
Rheumapraxis am Schlachtensee /ID# 287793
Berlin, 14129
- Recruiting
Klinikum Bielefeld Rosenhohe /ID# 283715
Bielefeld, North Rhine-Westphalia, 33647
- Recruiting
Mvz Dr. Med. Mahdy and Kollegen - Braunschweig /ID# 284988
Braunschweig, Lower Saxony, 38106
- Recruiting
Stadtisches Klinikum Braunschweig /ID# 282626
Braunschweig, Lower Saxony, 38126
- Recruiting
MVZ Herzogin Elisabeth Hospital /ID# 272725
Braunschweig, 38114
- Recruiting
Medizinischen Versorgungszentrums Agilomed /ID# 274887
Chemnitz, Saxony, 09130
- Recruiting
Private Practice - Dr. Sebastian Schuh /ID# 272731
Coburg, 96450
- Recruiting
MVZ-Medizinisches Versorgungszentrum Daun GmbH /ID# 285725
Daun, 54550
- Recruiting
Schwerpunktpraxis Rheumatologie und Klinische Immunologie /ID# 282628
Dresden, Saxony, 01097
- Recruiting
Rheumapraxis Düren /ID# 272726
Düren, 52355
- Recruiting
Praxis Dilltal /ID# 272727
Ehringshausen, 35630
- Recruiting
Medikomp Mvz /ID# 285898
Elsterwerda, Brandenburg, 04910
- Recruiting
Private Practice - Dr. Daniel Bestler /ID# 272741
Erfurt, 99096
- Recruiting
Praxisgemeinschaft Rheumatologie Nephrologie Erlangen /ID# 286648
Erlangen, Bavaria, 91056
- Recruiting
Rheumatology Euskirchen /ID# 285419
Euskirchen, North Rhine-Westphalia, 53879
- Recruiting
Deutsches Endokrinologisches Versorgungszentrum DEVZ - MVZ GdR /ID# 274291
Frankfurt am Main, Hesse, 60329
- Recruiting
Dr. Mueller /ID# 273081
Freiberg, Saxony, 09599
- Recruiting
Gemeinschaftspraxis Innere Medizin/Rheumatologie /ID# 278584
Freiburg im Breisgau, Baden-Wurttemberg, 79098
- Recruiting
Private Practice - Dr. Jorg Sensse /ID# 281907
Gifhorn, Lower Saxony, 38518
- Recruiting
Praxis Fiene /ID# 279410
Greifswald, 17493
- Recruiting
Rheumapraxis Dr. Liebhaber /ID# 274888
Halle, Saxony-Anhalt, 06128
- Recruiting
Private Practice - Dr Hauke E Heintz /ID# 278081
Hamburg, 22391
- Recruiting
Rheumatologische Facharztpraxis /ID# 286591
Hanover, Lower Saxony, 30159
- Recruiting
Rheumapraxis Hannover-List /ID# 273735
Hanover, Lower Saxony, 30161
- Recruiting
Praxis. F. Bigdeli-Wilshusen /ID# 273455
Hanover, Lower Saxony, 30173
- Recruiting
Rheumapraxis Heidelberg /ID# 276475
Heidelberg, Baden-Wurttemberg, 69120
- Recruiting
Rheumazentrum Ruhrgebiet /ID# 275518
Herne, North Rhine-Westphalia, 44649
- Recruiting
Private Practice - Dr. Dirk Wernicke /ID# 276820
Hohen Neuendorf, Brandenburg, 16540
- Recruiting
Rheumapraxis am Schlossberg /ID# 272728
Homburg, Saarland, 66424
- Recruiting
Praxis K. Pagel /ID# 279121
Hoppegarten, Brandenburg, 15366
- Recruiting
Praxis Dr. med. Florian Beyer /ID# 274293
Kaiserslautern, Rhineland-Palatinate, 67657
- Recruiting
Rheumatologie Kassel /ID# 275916
Kassel, Lower Saxony, 34125
- Recruiting
Rheumapraxis Kaufering /ID# 283852
Kaufering, 86916
- Recruiting
Private Practice - Dr. Frank Hamann, Dr. Andreas Teich & Dr. Konrad Boche /ID# 275358
Leipzig, Saxony, 04109
- Recruiting
Private Practice - Dr. Ilka Schwarze /ID# 276981
Leipzig, Saxony, 04129
- Recruiting
Dr. Ann-Dorthe Holst /ID# 285741
Ludwigslust, Mecklenburg-Vorpommern, 19288
- Recruiting
Rheumatologische Facharztpraxis - Magdeburg /ID# 272866
Magdeburg, Saxony-Anhalt, 39104
- Recruiting
Private Practice- Dr. Joerdis Gerigk /ID# 283747
Magdeburg, Saxony-Anhalt, 39106
- Recruiting
Dr. Harmuth /ID# 273401
Marktredwitz, Bavaria, 95615
- Recruiting
St.Elisabeth Hospital Meerbusch /ID# 275030
Meerbusch, North Rhine-Westphalia, 40668
- Recruiting
Gesundheitscampus Monheim /ID# 283726
Monheim am Rhein, North Rhine-Westphalia, 40789
- Recruiting
Praxiszentrum Dr. Med. Klaus Kruger Dres. Günther Kellerer Und Paul Kellerer /ID# 276138
Munich, Bavaria, 81541
- Recruiting
Prof-med-stud.de /ID# 285869
Munich, 80935
- Recruiting
Rheumatologische Facharztpraxis - Naumburg (Saale) /ID# 272743
Naumburg, Saxony-Anhalt, 06618
- Recruiting
Private Practice - Dr. Thilo Klopsch - Stargarder Strasse /ID# 276367
Neubrandenburg, Mecklenburg-Vorpommern, 17033
- Recruiting
Dr. Murawski /ID# 272724
Neunkirchen, Saarland, 66538
- Recruiting
Rheumapraxis An Der Hase /ID# 276949
Osnabrück, Lower Saxony, 49074
- Recruiting
Die Fachaerzte im Rottal - Nephrologie, Rheumatologie /ID# 284221
Pfarrkirchen, 84347
- Recruiting
Klinische Forschung Im Medizinischen Versorgungalltag Gbr /ID# 274587
Planegg, Bavaria, 82152
- Recruiting
Private Practice - Dr. Christine Baumann /ID# 275095
Plauen, Saxony, 08523
- Recruiting
Rheumahaus Studien GbR /ID# 275917
Potsdam, Brandenburg, 14467
- Recruiting
Knappschaftsklinikum Saar /ID# 279852
Püttlingen, Saarland, 66346
- Recruiting
Rheumapraxis Dr. Prothmann /ID# 279851
Püttlingen, Saarland, 66346
- Recruiting
Rheumazentrum Ratingen /ID# 275707
Ratingen, North Rhine-Westphalia, 40882
- Recruiting
Private Practice - Dr. Jochen Walter /ID# 280069
Rendsburg, Schleswig-Holstein, 24768
- Recruiting
Rheumatologische Facharztpraxis - Schwerin /ID# 284785
Schwerin, Mecklenburg-Vorpommern, 19053
- Recruiting
Rheumatologisch Immunologisch /ID# 275830
Templin, Brandenburg, 17268
- Recruiting
Rheumapraxis Haas Tubingen /ID# 275536
Tübingen, Baden-Wurttemberg, 72072
- Recruiting
Rheumapraxis Ulm Dr. med. Nadia Rinaldi /ID# 276293
Ulm, Baden-Wurttemberg, 89073
- Recruiting
Praxis F. Schattenberg /ID# 280322
Waren, 17192
- Recruiting
Rheumapraxis Weimar /ID# 272740
Weimar, Thuringia, 99427
- Recruiting
Fachpraxis fur Rheumatologie und Osteologie /ID# 275359
Weyhe, Lower Saxony, 28844
- Recruiting
Private Practice - Dr. Alexander Lautwein /ID# 282328
Wittlich, Rhineland-Palatinate, 54516
- Recruiting
Cellitinnen-Krankenhaus St. Josef /ID# 275926
Wuppertal, 42105
- Recruiting
Praxis Barmen /ID# 277514
Wuppertal, 42285
- Recruiting
Rheumapraxis Zweibruecken - Matar /ID# 282656
Zweibrücken, Rhineland-Palatinate, 66482
- Recruiting
Praxis H. Fricke-Wagner /ID# 274467
Zwickau, Saxony, 08056
About this study
Official title: Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care
This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany.
Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Keywords
- Moderate to Severe Rheumatoid Arthritis, Rheumatoid Arthritis, Upadacitinib, Tumor Necrosis Factor Inhibitor Treatment
- Medical subject headings
- Arthritis, Rheumatoid
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Upadacitinib | Participants will receive upadacitinib as prescribed by their physician according to local label. | |
| Tumor Necrosis Factor Inhibitor-Treatment | Participants will receive a tumor necrosis factor inhibitor treatment as prescribed by their physician according to local label. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Retention Rate of UPA vs TNFi
Time to the discontinuation of Upadacitinib. Time to the discontinuation of Tumor Necrosis Factor Inhibitor treatment
Measured: Up to approximately 24 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Dec 2024
- Study start7 Nov 2024
- Primary completionDec 2028 (estimated)
- Study completionDec 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Moderate to Severe Rheumatoid ArthritisStudies of the same condition, open and under way.
- More trials run by AbbVieThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 678 participants (estimated)
Sponsor and investigators
- Lead sponsor
- AbbVie
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- ABBVIE INC., Study director, AbbVie
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06712628
- Sponsor's protocol ID
- P25-188
- Acronym
- UP-RISING
- Status last verified
- Oct 2026
- First submitted
- 27 Nov 2024
- Last updated
- 15 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 15 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING
- ClinicalTrials.gov ID
- NCT06712628
- Acronym / sponsor ID
- UP-RISING / P25-188
- Conditions
- Moderate to Severe Rheumatoid Arthritis
- Keywords
- Moderate to Severe Rheumatoid Arthritis, Rheumatoid Arthritis, Upadacitinib, Tumor Necrosis Factor Inhibitor Treatment
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 678 participants (estimated)
- Lead sponsor
- AbbVieIndustry (pharma, biotech, devices)
- Study start
- 7 Nov 2024 (actual)
- Primary completion
- Dec 2028 (estimated)
- Study completion
- Dec 2028 (estimated)
- First posted
- 2 Dec 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study will compare the retention rates for UPA vs. TNFi treatment in adult participants with moderate to severe active RA per local label and according to local standard of care
This is a mono-country, prospective, multi-center observational study in patients with moderate to severe active RA receiving UPA or TNFi therapy. Around 678 participants will be enrolled in approximately 80 sites in Germany.
Study recruitment will last approximately 24 months, and the study participation time will be up to 24 months, for a total study duration of approximately 48 months.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Upadacitinib | – | –Participants will receive upadacitinib as prescribed by their physician according to local label. |
| Tumor Necrosis Factor Inhibitor-Treatment | – | –Participants will receive a tumor necrosis factor inhibitor treatment as prescribed by their physician according to local label. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Participants with moderate to severe active Rheumatoid Arthritis receiving Upadcitinib or a Tumor necrosis factor inhibitor treatment.
Key inclusion criteria (3 listed)
- Current or Past participants with a confirmed diagnosis of moderate to severe active RA upon judgement of the treating physician.
- Physician decision on participant treatment with Upadacitinib (UPA) or tumor necrosis factor inhibitor (TNFi) must have been reached prior to and independently of recruitment in the study
- UPA or TNFi prescribed in accordance with the applicable approved label and local regulatory and reimbursement policies
Key exclusion criteria (3 listed)
- Participation in a clinical trial with an investigational drug (within a minimum of 30 days or 5 half-lives of the investigational drug [whichever is longer] prior to baseline)
- Prior treatment with Upadacitinib
- Prior treatment with the same tumor necrosis factor inhibitor as the one prescribed for this study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Retention Rate of UPA vs TNFi
Time frame: Up to approximately 24 months
Time to the discontinuation of Upadacitinib. Time to the discontinuation of Tumor Necrosis Factor Inhibitor treatment
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Oct 2026.
- Individual participant dataSharing planned: Undecided
Related trials for Moderate to Severe Rheumatoid Arthritis
Active, not recruitingPhase 3
Nipocalimab in Moderate to Severe Sjogren's Disease
Sjogrens Syndrome
Not yet recruitingPhase 2
Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Rheumatoid Arthritis
Active, not recruitingObservational study
Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis
Rheumatoid Arthritis
RecruitingPhase 2
A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)
Rheumatoid Arthritis
RecruitingPhase 2
A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis
Rheumatoid Arthritis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
ABBVIE INC. study director
AbbVie
75 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Moderate to Severe Rheumatoid Arthritis, run by AbbVie at 75 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 75 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Medical Information Germany (49 611 1720 1520, medinfo.germany@abbvie.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Retention Rate of UPA vs TNFi (time frame: Up to approximately 24 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2026.